Beyond Air, Inc. (XAIR)

US — Healthcare Sector
Peers: LUCD  NARI  PAVMZ  CLPT    TBIO  RCEL  SGHT  TMCI  CTKB  HSKA  KIDS  ELMD  LUNG  TELA  CVRX  NPCE  TMDX  DCTH 

Automate Your Wheel Strategy on XAIR

With Tiblio's Option Bot, you can configure your own wheel strategy including XAIR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol XAIR
  • Rev/Share 0.0343
  • Book/Share 0.2087
  • PB 0.9155
  • Debt/Equity 0.1138
  • CurrentRatio 3.5624
  • ROIC -1.6675

 

  • MktCap 15840240.0
  • FreeCF/Share -0.5484
  • PFCF -0.3279
  • PE -0.3089
  • Debt/Assets 0.0588
  • DivYield 0
  • ROE -2.4059

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 3
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Beyond Air, Inc. (XAIR) Q3 2025 Earnings Call Transcript
XAIR
Published: February 10, 2025 by: Seeking Alpha
Sentiment: Neutral

Beyond Air, Inc. (NASDAQ:XAIR ) Q3 2025 Results Conference Call February 10, 2025 4:30 PM ET Company Participants Corey Davis - Investor Relations, LifeSci Advisors Steve Lisi - Chairman and Chief Executive Officer Doug Larson - Chief Financial Officer Conference Call Participants Jason Wittes - Roth Partners Sam Eiber - BTIG Jason Bednar - Piper Sandler Justin Walsh - JonesTrading Yale Jen - Laidlaw & Company Operator Good afternoon, and welcome everyone to the Beyond Air Financial Results Call for the Fiscal Quarter Ended December 31, 2024. At this time, all participants are in a listen-only mode.

Read More
image for news Beyond Air, Inc. (XAIR) Q3 2025 Earnings Call Transcript

About Beyond Air, Inc. (XAIR)

  • IPO Date 2018-06-12
  • Website https://www.beyondair.net
  • Industry Medical - Devices
  • CEO Mr. Steven Adam Lisi
  • Employees 107

Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.